<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2024-391</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-8617</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CHRONIC HEART FAILURE</subject></subj-group></article-categories><title-group><article-title>Роль физических тренировок в комплексной реабилитации у пациентов с хронической сердечной недостаточностью и сахарным диабетом 2-го типа</article-title><trans-title-group xml:lang="en"><trans-title>Role of physical training in cardiac rehabilitation in patients with congestive heart failure and type 2 diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7604-5481</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Синькова</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sinkova</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Синькова Маргарита Николаевна, к.м.н., доцент, доцент кафедры последипломной подготовки и сестринского дела</p><p>650056, Кемерово, ул. Ворошилова, д. 22а</p></bio><bio xml:lang="en"><p>Margarita N. Sinkova, Cand. Sci. (Med.), Assistant Professor, Department of Postgraduate Training and Nursing</p><p>22a, Voroshilov St., Kemerovo, 650029</p></bio><email xlink:type="simple">MargoV@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0487-3880</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исаков</surname><given-names>Л. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Isakov</surname><given-names>L. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Исаков Леонид Константинович, к.м.н., доцент, заведующий кафедрой последипломной подготовки и сестринского дела</p><p>650056, Кемерово, ул. Ворошилова, д. 22а</p></bio><bio xml:lang="en"><p>Leonid К. Isakov, Cand. Sci. (Med.), Head of Department of Postgraduate Training and Nursing</p><p>22a, Voroshilov St., Kemerovo, 650029</p></bio><email xlink:type="simple">isakovy@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6150-1808</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плотникова</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Plotnikova</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Плотникова Екатерина Юрьевна, д.м.н., профессор, профессор кафедры последипломной подготовки и сестринского дела</p><p>650056, Кемерово, ул. Ворошилова, д. 22а</p></bio><bio xml:lang="en"><p>Еkaterina Yu. Plotnikova, Dr. Sci. (Med.), Professor, Department of Postgraduate Training and Nursing</p><p>22a, Voroshilov St., Kemerovo, 650029</p></bio><email xlink:type="simple">eka-pl@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4642-3610</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барбараш</surname><given-names>О. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Barbarash</surname><given-names>O. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Барбараш Ольга Леонидовна, академик РАН, д.м.н., профессор, заведующий кафедрой кардиологии и сердечно-сосудистой хирургии</p><p>650056, Кемерово, ул. Ворошилова, д. 22а</p></bio><bio xml:lang="en"><p>Оlga L. Barbarash, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Professor, Head of the Department of Cardiology and Cardiovascular Surgery</p><p>22a, Voroshilov St., Kemerovo, 650029</p></bio><email xlink:type="simple">olb61@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кемеровский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kemerovo State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>30</day><month>10</month><year>2024</year></pub-date><volume>0</volume><issue>16</issue><fpage>101</fpage><lpage>107</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Синькова М.Н., Исаков Л.К., Плотникова Е.Ю., Барбараш О.Л., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Синькова М.Н., Исаков Л.К., Плотникова Е.Ю., Барбараш О.Л.</copyright-holder><copyright-holder xml:lang="en">Sinkova M.N., Isakov L.K., Plotnikova E.Y., Barbarash O.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/8617">https://www.med-sovet.pro/jour/article/view/8617</self-uri><abstract><sec><title>Введение</title><p>Введение. В настоящее время эффективность кардиореабилитации коморбидных пациентов с хронической сердечной недостаточностью (ХСН) с использованием физических тренировок при назначении оптимальной медикаментозной терапии, включающей препараты SGLT2, не изучена.</p></sec><sec><title>Цель</title><p>Цель. Изучить влияние контролируемых физических тренировок на качество жизни (КЖ) и прогноз пациентов с ХСН, коморбидной с сахарным диабетом (СД) 2-го типа на фоне рациональной фармакотерапии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включены 74 пациента с ХСН на фоне СД 2-го типа, получающих оптимальную медикаментозную терапию, с обязательным приемом препаратов SGLT2. Методом простой рандомизации сформированы 2 группы: «Физические тренировки» (n = 35) – базовая медикаментозная терапия дополнена программой контролируемых физических тренировок, и «Стандартная медикаментозная терапия» (n = 37) – только базовая медикаментозная терапия. Пациентам группы стандартной медикаментозной терапии рекомендованы регулярные аэробные физические нагрузки умеренной интенсивности по 30–60 мин как минимум 5 дней в нед.</p></sec><sec><title>Результаты</title><p>Результаты. В группе «Физические тренировки» через 12 мес. зарегистрировано увеличение дистанции по результатам теста 6-мин ходьбы на 39,6% (в среднем 407,2 м), в группе «Стандартная медикаментозная терапия» физическая толерантность возросла на 12,2% (324,5 м) (p = 0,002). По данным Миннесотского опросника КЖ у больных ХСН получены результаты, характеризующие высокую социальную адаптацию пациентов при проведении у них физических тренировок в сравнении со стандартной патогенетической медикаментозной терапией. Так, показатель КЖ в группе «Физические тренировки» в среднем изменился на 25,2 балла, а в группе «Стандартная медикаментозная терапия» – на 5,7 балла, составив в группе «Физические тренировки» 37,3 ± 5,9, в группе «Стандартная медикаментозная терапия» – 58,2 ± 2,1 (р = 0,001).</p></sec><sec><title>Выводы</title><p>Выводы. Физические тренировки у пациентов с ХСН, ассоциированной с СД 2-го типа на фоне оптимальной медикаментозной терапии, приводят к увеличению дистанции по результатам теста 6-минутной ходьбы и способствуют улучшению КЖ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Currently, the effectiveness of cardiac rehabilitation of patients with comorbid CHF using physical training when prescribing optimal drug therapy, including SGLT2 drugs, has not been studied.</p></sec><sec><title>Aims</title><p>Aims. To study the effect of controlled physical training on the quality of life and prognosis of patients with CHF comorbid with type 2 diabetes mellitus against the background of rational pharmacotherapy.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study included 74 patients with CHF against the background of type 2 diabetes mellitus, receiving optimal drug therapy, with mandatory intake of SGLT2 drugs. Two groups were formed using the simple randomization method: “Physical training” (n = 35) – basic drug therapy supplemented by a program of controlled physical training and “Standard drug therapy” (n = 37) – only basic drug therapy. Patients in the standard drug therapy group were recommended regular aerobic physical activity of moderate intensity for 30–60 minutes at least 5 days a week.</p></sec><sec><title>Results</title><p>Results. In the Physical Training group, after 12 months, an increase in the distance according to the results of the 6-minute walk test by 39.6% (on average 407.2 meters) was registered, in the Standard Drug Therapy group, physical tolerance increased by 12.2% (324.5 meters) (p = 0.002). According MLHFQ questionnaire in patients with CHF, the results were obtained that characterize the high social adaptation of patients during physical training in comparison with standard pathogenetic drug therapy. Thus, the MLHFQ indicator in the Physical Training group changed by an average of 25.2 points, and in the Standard Drug Therapy group – by 5.7 points, amounting to 37.3 ± 5.9 in the Physical Training group, and 58.2 ± 2.1 in the Standard Drug Therapy group (p = 0.001).</p></sec><sec><title>Conclusions</title><p>Conclusions. Physical training in patients with CHF associated with type 2 diabetes mellitus against the background of optimal drug therapy leads to an increase in the distance according to the results of the 6-minute walk test and contributes to an improvement in the quality of life.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>кардиореабилитация</kwd><kwd>оптимальная медикаментозная терапия</kwd><kwd>физические тренировки</kwd><kwd>качество жизни</kwd><kwd>препараты SGLT2</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cardiac rehabilitation</kwd><kwd>optimal drug therapy</kwd><kwd>physical training</kwd><kwd>quality of life</kwd><kwd>SGLT2 drugs</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Синьков МА, Кочергин НА, Ганюков ВИ. Госпитальные результаты лечения больных острым коронарным синдромом без подъема сегмента ST по данным реальной клинической практики. Комплексные проблемы сердечно-сосудистых заболеваний. 2019;8(1):23–29. https://doi.org/10.17802/2306-1278-2019-8-1-23-29.</mixed-citation><mixed-citation xml:lang="en">Sinkov MA, Kochergin NA, Ganyukov VI. Hospital outcomes in patients with non-ST-segment elevation acute coronary syndrome according to clinical practice. Complex Issues of Cardiovascular Diseases. 2019;8(1):23–29. (In Russ.) https://doi.org/10.17802/2306-1278-2019-8-1-23-29.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Несова АК, Рябов ВВ. Парадоксы острого коронарного синдрома без подъема сегмента ST в условиях реальной клинической практики. Российский кардиологический журнал. 2024;29(3):5623. https://doi.org/10.15829/1560-4071-2024-5623.</mixed-citation><mixed-citation xml:lang="en">Nesova AK, Ryabov VV. Paradoxes of non-ST-segment elevation acute coronary in real-life clinical practice settings. Russian Journal of Cardiology. 2024;29(3):5623. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5623.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Алекян БГ, Бойцов СА, Маношкина ЕМ, Ганюков ВИ. Реваскуляризация миокарда в Российской Федерации при остром коронарном синдроме в 2016–2020 гг. Кардиология. 2021;61(12):4–15. https://doi.org/10.18087/cardio.2021.12.n1879.</mixed-citation><mixed-citation xml:lang="en">Alekyan BG, Boytsov SA, Manoshkina EM, Ganyukov VI. Myocardial revascularization in Russian Federation for acute coronary syndrome in 2016–2020. Kardiologiya. 2021;61(12):4–15. (In Russ.) https://doi.org/10.18087/cardio.2021.12.n1879.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Синькова МН, Исаков ЛК, Синьков МА, Плотникова ЕЮ, Гуляева ЕН. Новое в реабилитации больных с хронической сердечной недостаточностью, ассоциированной с сахарным диабетом 2-го типа. Медицинский совет. 2020;(14):40–47. https://doi.org/10.21518/2079-701X-2020-14-40-47.</mixed-citation><mixed-citation xml:lang="en">Sinkova MN, Isakov LK, Sinkov MA, Plotnikova EY, Gulyaeva EN. New approach for the rehabilitation of patients with chronic heart failure associated with type 2 diabetes. Meditsinskiy Sovet. 2020;(14):40–47. (In Russ.) https://doi.org/10.21518/2079-701X-2020-14-40-47.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. https://doi.org/10.1056/NEJMc1600827.</mixed-citation><mixed-citation xml:lang="en">Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. https://doi.org/10.1056/NEJMc1600827.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018;137(2):119–129. https://doi.org/10.1161/CIRCULATIONAHA.117.028268.</mixed-citation><mixed-citation xml:lang="en">Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018;137(2):119–129. https://doi.org/10.1161/CIRCULATIONAHA.117.028268.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Neal B, Perkovic V, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. https://doi.org/10.1056/NEJMoa1611925.</mixed-citation><mixed-citation xml:lang="en">Neal B, Perkovic V, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. https://doi.org/10.1056/NEJMoa1611925.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. https://doi.org/10.1056/NEJMoa1812389.</mixed-citation><mixed-citation xml:lang="en">Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. https://doi.org/10.1056/NEJMoa1812389.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744.</mixed-citation><mixed-citation xml:lang="en">Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and metaanalysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. https://doi.org/10.1016/S0140-6736(18)32590-X.</mixed-citation><mixed-citation xml:lang="en">Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and metaanalysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. https://doi.org/10.1016/S0140-6736(18)32590-X.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–854. https://doi.org/10.1016/S2213-8587(19)30256-6.</mixed-citation><mixed-citation xml:lang="en">Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–854. https://doi.org/10.1016/S2213-8587(19)30256-6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Синькова МН, Исаков ЛК, Плотникова ЕЮ, Тарасов НИ. Влияние контролируемых физических тренировок на качество жизни больных хронической сердечной недостаточностью на фоне сахарного диабета 2-го типа. Дневник Казанской медицинской школы. 2018;(4):6–11. Режим доступа: https://dnevnik-kmsc.ru/kosmetologiya/item/556-vliyanie-kontroliruemykhfizicheskikh-trenirovok-na-kachestvo-zhizni-bolnykh-khronicheskojserdechnoj-nedostatochnostyu-na-fone-sakharnogo-diabeta-2-go-tipa.</mixed-citation><mixed-citation xml:lang="en">Sinkova MN, Isakov LK, Plotnikova EYu, Tarasov NI. The effect of controlled physical training on the quality of life of patients with chronic heart failure on the background of type 2 diabetes mellitus. Dnevnik Kazanskoy Meditsinskoy Shkoly. 2018;(4):6–11. (In Russ.) Available at: https://dnevnik-kmsc.ru/kosmetologiya/item/556-vliyanie-kontroliruemykhfizicheskikh-trenirovok-na-kachestvo-zhizni-bolnykh-khronicheskojserdechnoj-nedostatochnostyu-na-fone-sakharnogo-diabeta-2-go-tipa.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава ЖД, Ешниязов НБ, Медовщиков ВВ, Хасанова ЭР. Сахарный диабет 2-го типа и сердечная недостаточность: инновационные возможности управления прогнозом. Кардиология. 2019;59(4):76–87. https://doi.org/10.18087/cardio.2019.4.10253.</mixed-citation><mixed-citation xml:lang="en">Kobalava ZhD, Yeshniyazov NV, Medovchshikov VV, Khasanova ER. Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis. Kardiologiya. 2019;59(4):76–87. (In Russ.) https://doi.org/10.18087/cardio.2019.4.10253.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Агеев ФТ, Арутюнов ГП, Беграмбекова ЮЛ, Беленков ЮН, Бойцов СА, Васюк ЮА и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. https://doi.org/10.15829/1560-4071-2020-4083.</mixed-citation><mixed-citation xml:lang="en">Ageev FT, Arutyunov GP, Begrambekova YuL, Belenkov YuN, Boytsov SA, Vasyuk YuA et al. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) https://doi.org/10.15829/1560-4071-2020-4083.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190.</mixed-citation><mixed-citation xml:lang="en">Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77(11):1397–1407. https://doi.org/10.1016/j.jacc.2021.01.044.</mixed-citation><mixed-citation xml:lang="en">Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G et al. Interplay of mineralocorticoid receptor anta- gonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77(11):1397–1407. https://doi.org/10.1016/j.jacc.2021.01.044.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов ИИ, Шестакова МВ, Майоров АЮ, Шамхалова МШ, Сухарева ОЮ, Галстян ГР и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4–102. https://doi.org/10.14341/DM12507.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Mayorov AY, Shamkhalova MS, Sukhareva OYu, Galstyan GR et al. Diabetes mellitus type 2 in adults. Diabetes Mellitus. 2020;23(2S):4–102. (In Russ.) https://doi.org/10.14341/DM12507.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190.</mixed-citation><mixed-citation xml:lang="en">Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.</mixed-citation><mixed-citation xml:lang="en">McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Синькова МН, Пепеляева ТВ, Исаков ЛК, Тарасов НИ, Тепляков АТ. Отдаленные эффекты влияния омега-3 полиненасыщенных жирных кислот на течение ишемической болезни сердца у больных, перенесших инфаркт миокарда с подъемом сегмента st на фоне многососудистого стенозирующего атеросклероза коронарных артерий. Кардиоваскулярная терапия и профилактика. 2014;13(6):32–37. https://doi.org/10.15829/1728-8800-2014-6-32-37.</mixed-citation><mixed-citation xml:lang="en">Sinkova MN, Pepelyaeva TV, Isakov LK, Tarasov NI, Teplyakov AT. Long-term effects of omega-3-polyunsaturated fatty acid on the course of ischemic heart disease in patients after ST-elevation mioacardial infarction at the multiple-vessel lesion coronary atherosclerosis. Cardiovascular Therapy and Prevention (Russian Federation). 2014;13(6):32–37. (In Russ.) https://doi.org/10.15829/1728-8800-2014-6-32-37.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.</mixed-citation><mixed-citation xml:lang="en">McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Radhoe SP, Veenis JF, Linssen GCM, van der Lee C, Eurlings LWM, Kragten H et al. Diabetes and treatment of chronic heart failure in a large real-world heart failure population. ESC Heart Fail. 2022;9(1):353–362. https://doi.org/10.1002/ehf2.13743.</mixed-citation><mixed-citation xml:lang="en">Radhoe SP, Veenis JF, Linssen GCM, van der Lee C, Eurlings LWM, Kragten H et al. Diabetes and treatment of chronic heart failure in a large real-world heart failure population. ESC Heart Fail. 2022;9(1):353–362. https://doi.org/10.1002/ehf2.13743.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145–155. https://doi.org/10.1002/clc.23321.</mixed-citation><mixed-citation xml:lang="en">Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145–155. https://doi.org/10.1002/clc.23321.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Витт КН, Кужелева ЕА, Тукиш ОВ, Солдатенко МВ, Кондратьев МЮ, Огуркова ОН и др. Низкоинтенсивное воспаление как проявление коморбидности и фактор неблагоприятного клинического течения сердечной недостаточности с сохраненной фракцией выброса. Кардиоваскулярная терапия и профилактика. 2024;23(2):3847. https://doi.org/10.15829/1728-8800-2024-3847.</mixed-citation><mixed-citation xml:lang="en">Vitt KN, Kuzheleva EA, Tukish OV, Soldatenko MV, Kondratiev MYu, Ogurkova ON et al. Low-intensity inflammation as a manifestation of comorbidity and a factor in the unfavorable clinical course of heart failure with preserved ejection fraction. Cardiovascular Therapy and Prevention (Russian Federation). 2024;23(2):3847. (In Russ.) https://doi.org/10.15829/1728-8800-2024-3847.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Акчурин РС, Алекян БГ, Аронов ДМ, Беленков ЮН, Бойцов СА, Болдуева СА и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. Режим доступа: https://russjcardiol.elpub.ru/jour/article/viewFile/4076/3082.</mixed-citation><mixed-citation xml:lang="en">Akchurin RS, Alekyan BG, Aronov DM, Belenkov YuN, Boytsov SA, Boldueva SA et al. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) Available at: https://russjcardiol.elpub.ru/jour/article/viewFile/4076/3082.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ларина ВН, Скиба ИК, Ларин ВГ, Михайлусова МП, Скиба АС. Сердечная недостаточность с сохраненной фракцией выброса левого желудочка на фоне сахарного диабета: общие механизмы и возможная тактика терапии. CardioСоматика. 2022;13(2):115–123. https://doi.org/10.17816/CS110912.</mixed-citation><mixed-citation xml:lang="en">Larina VN, Skiba IK, Larin VG, Mikhailusova MP, Skiba AS. Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. Cardiosomatics. 2022;13(2):115–123. (In Russ.) https://doi.org/10.17816/CS110912.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023;329(10):827–838. https://doi.org/10.1001/jama.2023.2020.</mixed-citation><mixed-citation xml:lang="en">Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023;329(10):827–838. https://doi.org/10.1001/jama.2023.2020.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Акопян ЕС. Нагрузки в оздоровительной тренировке взрослых: допустимые величины и способы регулирования. Наука и спорт: современные тенденции. 2020;8(1):106–115. Режим доступа: https://cyberleninka.ru/article/n/nagruzki-v-ozdorovitelnoy-trenirovke-vzroslyh-dopustimyevelichiny-i-sposoby-regulirovaniya.</mixed-citation><mixed-citation xml:lang="en">Akopian ES. Training loads in recreational programs for adult people: permissible values and regulation techniques. Science and sport: current trends. 2020;8(1):106–115. (In Russ.) Available at: https://cyberleninka.ru/article/n/nagruzki-v-ozdorovitelnoy-trenirovke-vzroslyh-dopustimyevelichiny-i-sposoby-regulirovaniya.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Манукян МА, Фальковская АЮ, Мордовин ВФ, Рябова ТР, Зюбанова ИВ, Гусакова АМ, Суслова ТЕ. Особенности хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка у больных резистентной артериальной гипертонией в сочетании с сахарным диабетом 2-го типа. Сахарный диабет. 2021;24(4):304–314. https://doi.org/10.14341/DM12732.</mixed-citation><mixed-citation xml:lang="en">Манукян МА, Фальковская АЮ, Мордовин ВФ, Рябова ТР, Зюбанова ИВ, Гусакова АМ, Суслова ТЕ. Особенности хронической Manukyan MA, Falkovskaya AY, Mordovin VF, Ryabova TR, Zyubanova IV, Gusakova AM, Suslova TE. Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension. Diabetes Mellitus. 2021;24(4):304–314. (In Russ.) https://doi.org/10.14341/DM12732.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Качнов ВА, Тыренко ВВ, Кольцов АВ, Бологов СГ, Коцоева ОТ. Новый фенотип пациента с сердечной недостаточностью со «сверхнормальной фракцией выброса левого желудочка». Кардиологический вестник. 2023;18(3):16–22. https://doi.org/10.17116/Cardiobulletin20231803116.</mixed-citation><mixed-citation xml:lang="en">Kachnov VA, Tyrenko VV, Koltsov AV, Bologov SG, Kotsoeva OT. New phenotype of a patient with heart failure and «supra-normal left ventricular ejection fraction». Russian Cardiology Bulletin. 2023;18(3):16–22. (In Russ.) https://doi.org/10.17116/Cardiobulletin20231803116.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
